Slingshot members are tracking this event:
FDA Accepts Intercept’s (ICPT) NDA for Obeticholic Acid in Liver Fibrosis Due to NASH and Grants Priority Review
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Nov 25, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Obeticholic Acid, Nash Fibrosis, Liver Fibrosis